



**SOLVE
ON.**

Incyte Expands its Support for People Living with Vitiligo Launching Vitiligo Innovators Program™ in Conjunction with Incyte Ingenuity Awards in Vitiligo™

-Newly launched Vitiligo Innovators Program recognizes individuals who have made a positive impact on the vitiligo community

-2023 Incyte Ingenuity Awards in Vitiligo winners announced and applications opened for 2024 cycle

WILMINGTON, Del. – June 22, 2024 – As part of its commitment to supporting initiatives that foster innovation and honor outstanding contributions for the vitiligo community, Incyte is proud to announce the launch of the Vitiligo Innovators Program (VIP). This new program, the first of its kind for vitiligo at Incyte, provides an opportunity to honor exceptional individuals such as patients, caregivers, advocates, researchers, medical students, residents and/or healthcare providers, who have made remarkable contributions to the vitiligo community.

In addition to launching VIP, the Company is excited to announce UMass Chan Medical School, Department of Dermatology and Litty Ligo Vitiligo Community Network as the recipients of the 2023 Incyte Ingenuity Awards (IIA) in Vitiligo.

- UMass Chan Medical School, Department of Dermatology received the up to \$100,000 award to implement its project, *Removing Educational Equity Barriers for Individuals with Vitiligo*, which sets out to identify the gaps in public education in vitiligo, particularly for children and those who are non-native English language speakers through engaging and cutting-edge digital, visual public educational materials.
- The Litty Ligo Vitiligo Community Network received the up to \$35,000 award to implement *Beautiful Both Ways: A Celebration of You*, aimed at acknowledging and providing support for commonly reported obstacles by the vitiligo community such as maintaining a healthy body image, managing self-esteem and understanding mental health through an in-person community event.

"We are committed to empowering the vitiligo community through the Incyte Ingenuity Awards in Vitiligo and the new Vitiligo Innovators Program," said Matteo Trotta, Executive Vice President and General Manager, U.S. Dermatology, Incyte. "By supporting these impactful initiatives and recognizing individuals who have made significant strides in their unwavering commitment to this community, we believe we can truly make a difference for those living with this condition."

Individual nominations for VIP and applications for the 2024 IIA in Vitiligo are now open until October 31, 2024. To learn more visit vitiligoinnovatorsprogram.com or incyteingenuityawards.com/vitiligo.

About Vitiligo

Vitiligo is a chronic autoimmune condition characterized by depigmentation (loss of color) of skin that results from the loss of pigment-producing cells known as melanocytes. In the United States, more than 1.5 million people are diagnosed with vitiligo¹. The overall prevalence of the condition is estimated at approximately 2-3 million², with the majority of people with vitiligo (approximately 85%) having nonsegmental vitiligo³. Often misperceived as a cosmetic condition, vitiligo can have a profound impact on people's lives⁴.

About Incyte Dermatology

Incyte's science-first approach and expertise in immunology has formed the foundation of the company. Today, we are building on this legacy as we discover and develop innovative dermatology treatments to bring solutions to patients in need.

We strive to identify and develop therapies to modulate immune pathways driving uncontrolled inflammation to help restore normal immune function and bring the body closer to homeostasis. Specifically, our efforts in dermatology are focused on a number of immune-mediated dermatologic conditions with a high unmet medical need, including atopic dermatitis, vitiligo, hidradenitis suppurativa, lichen planus, lichen sclerosus, and prurigo nodularis

To learn more, visit the [Dermatology section](#) of [Incyte.com](#).

About Incyte

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For additional information on Incyte, please visit [Incyte.com](#) or follow us on social media: [LinkedIn](#), [X](#), [Instagram](#), [Facebook](#), [YouTube](#).

###

Contact:

Erica Cech
Director, Communications & Patient Advocacy
Tel: +1 302 498 7036
ecech@incyte.com

¹ Bergqvist C, Ezzedine K. Vitiligo: A Review. *Dermatology* 2020;236:571-592.

² Gandhi K, et al. Prevalence of vitiligo among adults in the United States. *JAMA Dermatol.* 2022;158(1):43-50.

³ Ezzedine K, et al. Seminar: Vitiligo. *Lancet* 2015;386:74–84.

⁴ Bowcock A, et al. Targeting skin: vitiligo and autoimmunity. *J Invest Dermatol.* 2012;132(1):13-15.